hsa-miR-200a

ncRNA information

ncRNA name

hsa-miR-200a

Specific or universal ncRNAs

Specific ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Not available

Downstream target

Not available

Cancer information

Cancer name

Non-Small Cell Lung Cancer

Cancer site

Lung

Treatment information

Treatment type

Chemotherapy

Drug

Gefitinib

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Down

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

Moreover, in NSCLC cell lines that are resistant to gefitinib, a drug often used in TKI therapies to treat NSCLC, miR-200a expression is able to render the cells much more sensitive to the drug treatment.

Tissue resource

human normal lung cell lines MRC-5

human normal lung cell lines CCD-19Lu

human lung cancer cell lines H3255

human lung cancer cell lines H1975

human lung cancer cell lines HCC827

Experiment

qRT-PCR,Western blot


Institute

American Type Culture Collection

Country

USA

Continent

Amercia